An interventional study of BCG and Gemcitabine in Non-muscle-invasive Bladder Cancer, sponsored by Al-Azhar University. Recruiting at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2024-02-13.
Sponsored by Al-Azhar University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing BCG Vaccine in Non-Muscle Invasive Bladder Neoplasms — 6 open to participants now, 12 under way, 5 of them phase 3. BCG Vaccine · Non-Muscle Invasive Bladder Neoplasms.
Among the 17 studies testing BCG Vaccine in Non-Muscle Invasive Bladder Neoplasms, this one is the 6th largest by planned enrollment, is the only one that started in 2021, is the only one with no phase, reaches primary completion later than 0 of the 11 other live ones, and was the 8th registered.
295 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 127 are open to participants now.
Browse Non-Muscle Invasive Bladder Neoplasms studies →6 of the 17 studies testing BCG Vaccine in Non-Muscle Invasive Bladder Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Australia and 16 more countries
Ages 18+
Chengdu CoenBiotech Co., Ltd · Sites in China
Ages 18–75
ImmunityBio, Inc.
Ages 18+
Queen's University · Sites in Canada
Ages 65+
By country, each count listing its studies:
BCG Vaccine: first FDA approval 1989 (N/A). What it is approved for, and how studies give it, is on its page →
Of the 93 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 78 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 7 · Phase 4 2
First in 1995; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 280 is above the median of 61 across 232 interventional studies indexed under Non-Muscle Invasive Bladder Neoplasms.
Median enrollment 160 across the 17 interventional studies. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 17 have an industry lead sponsor. The 10 most frequent:
Al-Azhar University is the lead sponsor of 536 studies on the registry; 172 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Al-Azhar University has 1 study filed under Non-Muscle Invasive Bladder Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies testing BCG Vaccine in Non-Muscle Invasive Bladder Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06829823ImmunityBio, Inc.Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer | 2026-11 |
| NCT07064863Queen's UniversityA Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC. | 2027-07-31 |
| NCT04179162Memorial Sloan Kettering Cancer CenterBacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies testing BCG Vaccine in Non-Muscle Invasive Bladder Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
About 40%-80% of NMIBC recur within 6-12 months when managed with TURBT alone, and 10%-25% of the patient's progress to muscle invasive disease. Intravesical therapy enables delivery of high local concentrations of a therapeutic agent within the bladder, which could potentially destroy viable tumor cells that remain following TURBT
Bladder cancer (BC) is the tenth most commonly diagnosed cancer worldwide. Approximately 75% of patients with BC present with disease confined to the mucosa (stage Ta or CIS) or submucosa (stage T1); for younger patients (\<40 year) this Percentage is even higher (Babjuk et al., 2022).
About 40%-80% of NMIBC recur within 6-12 months when managed with TURBT alone, and 10%-25% of the patient's progress to muscle invasive disease. Intravesical therapy enables delivery of high local concentrations of a therapeutic agent within the bladder, which could potentially destroy viable tumor cells that remain following TURBT (Ye Z, et al., 2018 and Daneshmand et al., 2022).
The Intravesical BCG injection can reduce the recurrence rate by about 30-40%. For intravesical therapy, chemotherapy drugs such as mitomycin C, gemcitabine, and epirubicin can be used post-TURBT, which is a good alternative treatment for BCG or a second-line treatment (Ansari et al., 2022).
The BCG vaccine was firstly developed by Albert Calmette over a hundred years ago. Its effect on bladder cancer was proposed by Dr. Alvaro Morales about forty years ago. In 1990, BCG was approved by the Food and Drug Administration (FDA) for the treatment of NMIBC and then became the first-line drug in NMIBC up to now (Ansari et al., 2022).
Due to worldwide shortage of BCG, there is a clinical need to develop novel intravesical agents and application forms in order to improve the oncological outcomes in non-muscle invasive bladder cancer (NMIBC). Gemcitabine has been investigated in various clinical trials. It has proven to be superior to BCG re-challenge and mitomycin (MMC) in BCG-unresponsive high-risk NMIBC (Gakis, 2022).
Gemcitabine is a nucleoside analogue with cytotoxic activity mediated by inhibition of DNA synthesis followed by cell apoptosis. The majority of trials examining gemcitabine have been in the setting of prior BCG failure (Balasubramanian et al., 2022).
NMIBC represents a significant global therapeutic challenge, particularly in the era of international BCG shortage due to manufacturing issues. Induction and maintenance intravesical BCG remains the historical gold standard for patients with intermediate or high-risk NMIBC. However, clinicians may be forced to consider alternatives given the current BCG shortage. Attempts to rationalize its use, including dose frequency reduction, have resulted in inferior outcome. Accordingly, there is considerable interest worldwide in assessing alternate approaches to improve oncologic outcomes for patients with NMIBC (Balasubramanian et al., 2022).
The majority of trials examining gemcitabine have been in the setting of prior BCG failure. To our knowledge there are only four trials evaluating initial intravesical gemcitabine without prior BCG usage. Porena et al., 2010 included only 32 patients; Bendary et al. 2011 included 40 patients; Gontero et al., 2013 included 61 patients and Prasanna et al., 2017 included 51 patients. Depending on this fact, we need a well-designed prospective trial including a large number of patients with reasonable follow-up period to estimate the actual benefits and hazards of intravesical gemcitabine injection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intravsical induction and maintenance BCG injections.
Drug: BCG
Intravsical induction and maintenance gemcitabin injections.
Drug: Gemcitabine
Intravsical induction and maintenance BCG injections.
Intravsical induction and maintenance gemcitabin injections.
Recurrence free survival (RFS)
time from the commencement of induction treatment to recurrence. All recurrences will be confirmed by cystoscopic guided biopsy and histology.
Time frame: 2 YEARS
Progression free survival (PFS)
progression in the initial tumour staging during follow-up cystoscopy. All progressions will be confirmed by histopathologic evaluation.
Time frame: 2 YEARS
Side effects of intravesical gemcitabine injection.
Side effects of intravesical gemcitabine injection will be measures according to the " Common Terminology Criteria for Adverse Events (CTCAE)" Version 5.0 Published on November 27, 2017 by the U.S. department of health and human services
Time frame: 2 YEARS
Side effects of intravesical BCG injection.
Side effects of intravesical BCG injection will be measures according to the " Common Terminology Criteria for Adverse Events (CTCAE)" Version 5.0 Published on November 27, 2017 by the U.S. department of health and human services
Time frame: 2 YEARS
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2021 (actual). Primary completion is estimated for Sep 2024, 44 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: BCG Vaccine · Gemcitabine
Non-Muscle Invasive Bladder Neoplasms →